GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemagen Diagnostics Inc (OTCPK:HMGN) » Definitions » Cash Conversion Cycle

Hemagen Diagnostics (Hemagen Diagnostics) Cash Conversion Cycle : 252.83 (As of Sep. 2012)


View and export this data going back to . Start your Free Trial

What is Hemagen Diagnostics Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Hemagen Diagnostics's Days Sales Outstanding for the three months ended in Sep. 2012 was 61.09.
Hemagen Diagnostics's Days Inventory for the three months ended in Sep. 2012 was 262.78.
Hemagen Diagnostics's Days Payable for the three months ended in Sep. 2012 was 71.04.
Therefore, Hemagen Diagnostics's Cash Conversion Cycle (CCC) for the three months ended in Sep. 2012 was 252.83.


Hemagen Diagnostics Cash Conversion Cycle Historical Data

The historical data trend for Hemagen Diagnostics's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hemagen Diagnostics Cash Conversion Cycle Chart

Hemagen Diagnostics Annual Data
Trend Sep03 Sep04 Sep05 Sep06 Sep07 Sep08 Sep09 Sep10 Sep11 Sep12
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 205.51 183.64 186.92 166.21 206.02

Hemagen Diagnostics Quarterly Data
Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 190.40 184.50 217.58 308.46 252.83

Competitive Comparison of Hemagen Diagnostics's Cash Conversion Cycle

For the Biotechnology subindustry, Hemagen Diagnostics's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hemagen Diagnostics's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemagen Diagnostics's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Hemagen Diagnostics's Cash Conversion Cycle falls into.



Hemagen Diagnostics Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Hemagen Diagnostics's Cash Conversion Cycle for the fiscal year that ended in Sep. 2012 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=52.74+212.18-58.9
=206.02

Hemagen Diagnostics's Cash Conversion Cycle for the quarter that ended in Sep. 2012 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=61.09+262.78-71.04
=252.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hemagen Diagnostics  (OTCPK:HMGN) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Hemagen Diagnostics Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Hemagen Diagnostics's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Hemagen Diagnostics (Hemagen Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
9033 Red Branch Road, Columbia, MD, USA, 21045
Hemagen Diagnostics Inc is a biotechnology company. It develops, manufactures and markets Food and Drug Administration cleared proprietary medical diagnostic test kits and components. The company's Virgo line of Immunoassays are used to aid in the diagnosis of autoimmune and infectious diseases and acute-phase proteins. The assays utilize multiple technologies including ELISA, immunofluorescence (IFA) and hemagglutination (HA). Its products include ANA Screen ELISA 96 Test System, Rubella IgG ELISA 96 Test System, AMA IFA 48 Test System and others.
Executives
Howard F Curd director

Hemagen Diagnostics (Hemagen Diagnostics) Headlines

No Headlines